Good morning :)
Place Order
Add to Watchlist

Strides Pharma Science Ltd

STAR Share Price

906.200.00% (+0.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹8,351 cr, stock is ranked 621

Stock is 3.61x as volatile as Nifty

STAR Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹8,351 cr, stock is ranked 621

Stock is 3.61x as volatile as Nifty

STAR Performance & Key Metrics

STAR Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
26.753.230.44%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.806.510.80%

STAR Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 2 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

STAR Company Profile

Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech

STAR Similar Stocks (Peers)

Compare with peers Compare with peers 

STAR Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.93
37.93
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
PE Ratio
22.84
22.84
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
PE Ratio
60.91
60.91
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
PE Ratio
54.95
54.95
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
PE Ratio
18.55
18.55
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
Compare with Peers

STAR Sentiment Analysis

STAR Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

STAR Stock Summary · May 2025

The company has demonstrated remarkable financial resilience, achieving record profits and a 17.2% revenue growth, driven by strong operational efficiency and a strategic focus on product innovation. With a robust pipeline of over 150 Abbreviated New Drug Applications and significant potential in the controlled substance nasal spray segment, management is optimistic about future U.S. market expansion. Despite challenges in access markets and rising costs associated with new product filings, the commitment to maintaining a strong balance sheet and reducing gross debt underscores a proactive approach to financial health. The emphasis on R&D investments and automation enhances operational capacity, positioning the company favorably for sustained growth and improved EBITDA margins in the coming years.

STAR Stock Growth Drivers
STAR Stock Growth Drivers
7
  • Strong Financial Performance

    The company reported a robust financial performance for FY '25, achieving a revenue growth of

  • Operational Efficiency and Consistency

    The company has demonstrated significant operational efficiency, achieving consistent quarter-on-quarter EBITDA growth over the past

STAR Stock Challenges
STAR Stock Challenges
4
  • Debt Management Challenges

    The company currently has a total debt of INR 1,800 crores and a net debt

  • Capital Expenditure Constraints

    The company plans to reduce capital expenditures (capex) for FY '26 to lower levels than

STAR Forecast

STAR Forecasts

Price

Revenue

Earnings

STAR

STAR

Income

Balance Sheet

Cash Flow

STAR Income Statement

STAR Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 22.18%, vs industry avg of 10.15%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.16% to 1.9%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 150.56%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue3,097.803,534.852,545.662,909.443,518.843,258.103,935.353,979.987,921.074,661.31
Raw Materialssubtract1,432.251,286.651,189.201,167.291,686.501,407.041,629.551,705.992,163.973,818.65
Power & Fuel Costsubtract33.8751.3354.3964.4964.5871.5485.8275.1358.17
Employee Costsubtract419.16434.05329.44442.56550.15646.91732.02737.05862.76
Selling & Administrative Expensessubtract339.47409.34276.20338.51473.78577.98526.31412.58518.06
Operating & Other expensessubtract54.45313.14196.74525.2598.10797.39724.88620.57201.96
Depreciation/Amortizationsubtract126.15154.04117.39173.70206.29233.01243.25213.64192.26194.32
Interest & Other Itemssubtract183.10196.2479.29155.72150.07176.74261.14280.22248.85256.71
Taxes & Other Itemssubtract109.6025.55-21.605.5320.94-192.30-65.005.4181.5879.41
EPS18.9731.5015.631.7813.12-22.47-9.86-3.40238.0733.88
DPS1.910.851.316.131.100.000.661.104.001.09
Payout ratio0.100.030.083.450.080.000.020.03

STAR Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual Report Unavailable

Investor Presentation

Sep 30PDF
 

STAR Stock Peers

STAR Past Performance & Peer Comparison

STAR Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Strides Pharma Science Ltd2.323.230.44%
Sun Pharmaceutical Industries Ltd37.935.720.93%
Cipla Ltd22.843.851.07%
Torrent Pharmaceuticals Ltd60.9115.340.93%

STAR Stock Price Comparison

Compare STAR with any stock or ETF
Compare STAR with any stock or ETF
STAR
Loading...

STAR Holdings

STAR Shareholdings

STAR Promoter Holdings Trend

STAR Promoter Holdings Trend

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 2.46%

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

STAR Institutional Holdings Trend

STAR Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

STAR Shareholding Pattern

STAR Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding28.30%8.89%4.83%28.32%29.66%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

STAR Shareholding History

STAR Shareholding History

Dec '23MarJunSepDec '24Mar19.45%24.57%26.71%30.08%28.48%28.32%

Mutual Funds Invested in STAR

Mutual Funds Invested in STAR

No mutual funds holding trends are available

Top 5 Mutual Funds holding Strides Pharma Science Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.5838%1.01%0.12%25/119 (+2)
1.5254%1.26%0.25%51/86 (-32)
0.9580%0.62%0.04%163/210 (0)

Compare 3-month MF holding change on Screener

STAR Insider Trades & Bulk Stock Deals

STAR Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing STAR stock

smallcases containing STAR stock

Looks like this stock is not in any smallcase yet.

STAR Events

STAR Events

STAR Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

STAR Dividend Trend

No dividend trend available

STAR Upcoming Dividends

STAR Upcoming Dividends

Cash Dividend

Ex DateEx DateJul 22, 2025

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Jul 22, 2025

STAR Past Dividends

STAR Past Dividends

Cash Dividend

Ex DateEx DateSep 9, 2024

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Sep 9, 2024

Cash Dividend

Ex DateEx DateAug 4, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Aug 4, 2023

Cash Dividend

Ex DateEx DateAug 5, 2021

Final
Final | Div/Share: ₹2.50

Dividend/Share

2.50

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateJul 24, 2020

Final
Final | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Jul 24, 2020

Cash Dividend

Ex DateEx DateAug 22, 2019

Interim
Interim | Div/Share: ₹12.00

Dividend/Share

12.00

Ex DateEx Date

Aug 22, 2019

STAR Stock News & Opinions

STAR Stock News & Opinions

Corporate
Strides Pharma Science schedules AGM

Strides Pharma Science announced that the 34th Annual General Meeting(AGM) of the company will be held on 7 August 2025.Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Strides Pharma Science fixes record date for final dividend

Strides Pharma Science has fixed 22 July 2025 as record date for final dividend of Rs 4 per share of face value of Rs 10 each for FY 2025. Powered by Capital Market - Live

6 days agoCapital Market - Live
Corporate
Board of Strides Pharma Science recommends final dividend

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter

Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1190.391043.50 14 4565.343890.13 17 OPM %18.3016.23 -17.5813.58 - PBDT182.6684.69 116 614.52287.89 113 PBT133.8036.76 264 422.2674.25 469 NP82.1918.18 352 3593.46-70.62 LP Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Strides Pharma Science to announce Quarterly Result

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Strides Pharma's US arm acquires four drugs to bolster portfolio

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy. Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products. The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore). Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products The company's consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24. The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Strides Pharma Science announces incorporation of step-down subsidiary

Arco Lab, a wholly owned subsidiary of Strides Pharma Science has incorporated a new wholly owned subsidiary viz., 'Pivot Path' on 10 April 2025. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Strides Pharma Science announces acquisition of Singapore-based Amexel

Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform. SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10. Amexel, as WOS of SPG, shall focus on: 'h - in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides'' manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. 'h - identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. 'h - building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories. Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Strides Pharma Science announces change in directorate

Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025. Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025. Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Strides Pharma Science appoints director

Strides Pharma Science has appointed Mukta Arora (DIN: 07225715) as Independent Director of the Company effective 01 February 2025. Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Strides Pharma Science Ltd (STAR) today?

    The share price of STAR as on 15th July 2025 is ₹906.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Strides Pharma Science Ltd (STAR) share?

    The past returns of Strides Pharma Science Ltd (STAR) share are
    • Past 1 week: 3.98%
    • Past 1 month: 2.13%
    • Past 3 months: 46.30%
    • Past 6 months: 47.07%
    • Past 1 year: 127.92%
    • Past 3 years: 508.94%
    • Past 5 years: 390.79%

  3. What are the peers or stocks similar to Strides Pharma Science Ltd (STAR)?
  4. What is the dividend yield % of Strides Pharma Science Ltd (STAR) share?

    The current dividend yield of Strides Pharma Science Ltd (STAR) is 0.44.

  5. What is the market cap of Strides Pharma Science Ltd (STAR) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Strides Pharma Science Ltd (STAR) is ₹8351.79 Cr as of 15th July 2025.

  6. What is the 52 week high and low of Strides Pharma Science Ltd (STAR) share?

    The 52-week high of Strides Pharma Science Ltd (STAR) is ₹929.60 and the 52-week low is ₹394.17.

  7. What is the PE and PB ratio of Strides Pharma Science Ltd (STAR) stock?

    The P/E (price-to-earnings) ratio of Strides Pharma Science Ltd (STAR) is 2.32. The P/B (price-to-book) ratio is 3.23.

  8. Which sector does Strides Pharma Science Ltd (STAR) belong to?

    Strides Pharma Science Ltd (STAR) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Strides Pharma Science Ltd (STAR) shares?

    You can directly buy Strides Pharma Science Ltd (STAR) shares on Tickertape. Simply sign up, connect your demat account and place your order.